It is characterized by narrowing of the airways in response to physical activity or exercise.
| Summary: exercise-induced bronchospasm (BIE) is a common condition that affects many people, especially those with asthma. It is characterized by narrowing of the airways in response to physical activity or exercise, which causes symptoms such as coughing, wheezing, shortness of breath, and chest tightness. Pharmacists play a critical role in the management of BNN, including educating patients on the correct use of inhaled corticosteroids and bronchodilators, screening for potential adherence problems, and advising on the correct prescribing of medications. They may also counsel patients on EIB prevention and treatment strategies, including warming up, avoiding triggers, and managing symptom escalation. Working in collaboration with medical teams, |
Introduction
According to the CDC, 4.9 million patients visit their doctors each year for asthma, and 1.2 million patients diagnosed with asthma go to the emergency room. exercise-induced bronchospasm (BIE) is a common condition that can affect patients with or without a diagnosis of asthma. Physical exercise can cause shortness of breath in most people; however, asthma sufferers also experience a feeling of tightness in the lungs, which makes it difficult to breathe. Up to 90% of patients diagnosed with asthma also have BNB, indicating its widespread prevalence. In order to adequately advise patients on drug therapy, pharmacists and physicians must have a complete understanding of the mechanism and symptoms of EIB.
Prevalence and risk factors
The Asthma and Allergy Foundation of America estimates that approximately 25 million Americans, or nearly one in 13 people, have asthma. EIB can occur in both asthmatic and non-asthmatic patients; however, it is believed that this affects approximately 90% of asthmatics. Children are a common group of victims. EIB is present in 40–90% of children with asthma, especially children with severe asthma who do not receive adequate medical therapy. Given the prevalence of asthma, it is critical that health care providers be familiar with the risk factors for EIB.
Additional risk factors for EIB include allergies, allergic rhinitis, and a history of asthma or wheezing. Because EIB is caused by exercise, strenuous exercise and sports can cause bronchospasm and constriction due to rapid breathing. The likelihood of BIE occurring is also affected by environmental variables. Factors such as humidity, cold air, and pollutants are associated with an increased risk of EIB. Breathing in cold environments often contributes significantly to EIB and is common in those exposed to cold, dry air.
Mechanism of action
It is necessary to understand the mechanism of action of EIB to ensure that an appropriate treatment option is prescribed. Two proposed mechanisms for the occurrence of EIB: drying of the airways and cooling of the mucous membrane. When the fluid on the surface of the airways in the lungs dries up due to excessive breathing caused by exercise, coughing and mucus production increase. This loss of water causes hyperosmolar medium, displacing water from the cell and thereby reducing it. As a result, they are released inflammatory mediators such as histamines, prostaglandins and leukotrienes. In addition, when mucus is cooled by breathing, cholinergic receptors in the airways are stimulated, resulting in increased mucus production and smooth muscle tone. These dual mechanisms feed off each other, causing bronchoconstriction during exercise.
Recognition of signs of EIB
Signs and symptoms of EIB are common indistinguishable asthma symptoms. The distinguishing feature between the two is the onset of these symptoms after 5–10 minutes of exercise. Patients with PEU experience symptoms such as chest tightness, shortness of breath, cough, wheezing, and shortness of breath. In addition, these symptoms usually disappear after 30 to 90 minutes and cause refractory period 1 to 3 hours.
Treatment Options for EIB
Although EIB is considered an asthmatic disease, the treatment process is somewhat different for patients with asthma. ok one than in patients with comorbid asthma and EIB. Patients with PEU only are usually recommended short-acting inhaled beta-2 agonist (SABA) use 5 to 20 minutes before to start the exercise. However, if these patients eventually require daily SABA, it would be more effective to add a control medication such as inhaled corticosteroid (X).
For patients with BI and asthma diagnosed, the addition of a control agent such as inhaled corticosteroid (ICS) is used daily. Use of small doses inhaled budesonide and formoterol pre-exercise, in contrast to pre-exercise CABA monotherapy, was better at reducing symptoms of BNV, according to a 6-week study of ICS with formoterol in people with moderate asthma. In addition, use of ICS-formoterol has been found to be non-inferior in reducing EIB compared to daily use of ICS and SABA as needed. These treatment options serve as a baseline and may need to be adjusted to resolve symptoms. In addition, patients with seasonal allergies take oral antihistamines daily before exercise.
